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In view of the well-established anti-inﬂammatory properties of latex of Calotropis procera (DL), the present study was carried
out to evaluate the protective eﬀect of its methanol extract (MeDL) against inﬂammation and oxidative stress in monoarthritis
induced by Freund’s complete adjuvant (FCA) in rats. Intra-articular injection of FCA produced inﬂammation of the joint with
a peak eﬀect occurring on day 4 where a maximum increase in the levels of myeloperoxidase and inﬂammatory mediators like
PGE2,T N F - α, and nitric oxide was observed. This was associated with oxidative stress with a marked reduction in the levels of
glutathione,catalase,superoxidedismutaseandglutathioneperoxidaseandanincreaseinthelipidperoxidationasindicatedbythe
higher levels of thiobarbituric acid reactive substances (TBARSs). Subsequently on day 28 the histological analysis of the joint also
revealed arthritic changes. Daily treatment of rats with MeDL (50 and 500mg/kg) and standard anti-inﬂammatory drug rofecoxib
(20 and 100mg/kg), produced a signiﬁcant attenuation in the inﬂammatory response and ameliorated the arthritic changes in
the joint. The protection aﬀorded by MeDL and rofecoxib was more pronounced than that of phenylbutazone and was associated
with normalization of the levels of inﬂammatory mediators and biochemical parameters of oxidative stress. However, the overall
protection aﬀorded by rofecoxib was better than that of MeDL.
Copyright © 2007 V. L. Kumar and S. Roy. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1. INTRODUCTION
The incidence of degenerative and inﬂammatory joint dis-
eases, namely osteoarthritis and rheumatoid arthritis, is very
high over the world [1, 2]. Typically arthritis is a com-
mon inﬂammatory disorder of the joint characterized by in-
ﬂammation of the synovial membrane, pain, and restricted
joint movement. Experimentally arthritis could be induced
by various inﬂammagens of which Freund’s complete adju-
vant (FCA) is the most commonly used agent [3, 4]. Intra-
articular injection of FCA is known to induce inﬂammation
as well as immune response and to produce features that re-
semble rheumatoid arthritis in humans. The acute inﬂam-
matory response induced by FCA is associated with leuko-
cyte inﬁltration, mast cell activation, and release of cytokines
and free radicals [5, 6]. This process gets aggravated with
macrophage activation and secretion of bioactive products
that play an important role in tissue destruction, vascular
proliferation, and ﬁbrosis over a period of time [7].
The role of cytokines like IL-1, IL-6, tumor necrosis
factor-α (TNF-α), prostaglandins (PGs), and nitric oxide
(NO)inarthritishasbeenwellestablished.Thelevelsofthese
inﬂammatory mediators have been reported to be high in
both experimental models of arthritis and in patients suf-
fering from arthritis [8, 9]. Besides, generation of reactive
oxygen species (ROS) and other free radicals also contribute
to the pathogenesis of arthritis [10]. In view of the un-
derlying mechanisms, both nonsteroidal and steroidal anti-
inﬂammatory drugs are used for the management of arthri-
tis[11].However,duetosideeﬀectsassociatedwiththelong-
termuseoftheseagents,manypatientstendtousealternative
therapeutic approaches including herbal therapies that have
been considered safe and eﬀective in alleviating chronic pain
associated with arthritis [12].
Calotropis procera (Ait.) R. Br., a wild growing plant of
family Asclepiadaceae, is well known for its medicinal prop-
erties. Diﬀerent parts of this plant have been reported to
exhibit anti-inﬂammatory, analgesic, and antioxidant prop-
erties [13]. The latex of this plant produces potent anti-
inﬂammatory, analgesic, and weak antipyretic eﬀects in var-
ious animal models [14–16]. Both latex and its methanol ex-
tract (MeDL) have been shown to inhibit inﬂammatory cell2 Mediators of Inﬂammation
inﬂux and edema formation induced by various inﬂamma-
gens [17]. It also improves locomotor functions in experi-
mentally induced monoarthritis in rats (unpublished ﬁnd-
ings). In view of these properties, the present study was car-
ried out to evaluate the eﬀect of MeDL on the levels of PGE2,
TNF-α, nitric oxide (NO), myeloperoxidase (MPO), oxida-
tive stress parameters, and joint histology in FCA-induced
monoarthritisinrats.TheeﬀectofMeDLwascomparedwith
rofecoxib, a selective COX-2 (cyclooxygenase-2) inhibitor,
and phenylbutazone (PBZ) a nonselective COX inhibitor.
2. MATERIALS AND METHODS
2.1. Plantmaterialanddrugs
The C. procera plant was identiﬁed by the Raw Materi-
als, Herbarium and Museum Division, National Institute
of Science and Communication, CSIR, New Delhi, where a
voucher specimen is preserved (Voucher no. PID 1739). The
latex was collected from the aerial parts of the plant growing
in the wild. It was dried under shade at ambient temperature
and was soxhlated to obtain methanol extract (MeDL) [18].
The MeDL was triturated with gum acacia used as suspend-
ing agent (1 : 1) in normal saline (NS), and administered
orally to rats at doses ranging from 50 to 500mg/kg (MeDL
50 and MeDL 500). Rofecoxib was administered orally at 20
and 100mg/kg doses (Rofe 20 and Rofe 100) and phenylbu-
tazone at a dose of 100mg/kg (PBZ). The drugs used in
the study were obtained from Arbro Pharmaceuticals (New
Delhi,India)(rofecoxibandphenylbutazone).Freund’scom-
plete adjuvant was obtained from Sigma-Aldrich Corpora-
tion (Bangalore, India).
2.2. Animals
The study was carried out on 5-6-month-old Wistar rats of
either sex weighing 150–180g. The rats were obtained from
the Experimetal Animal Facility of the Institute, were kept at
ambient temperature, and had free access to water and diet.
The animal experiments were carried in accordance with the
guidelines of Institutional Animal Ethics Committee.
2.3. Experimentaldesign
Monoarticular arthritis was induced in rats by injecting
0.1mL of 0.1% FCA (Sigma Aldrich, USA) into the intra-
articular space of right ankle joint (day 0) [19]. The increase
in joint diameter was measured daily starting from day 0, us-
ing a screw gauge till the time of peak inﬂammation (day 4),
and then it was measured every fourth day for a period of 28
days. The rats were divided into seven groups, consisting of
six animals each for analysis of histological and biochemical
parameters. Group I: normal control;Group II: FCA control.
In Group III to Group VII, drugs were administered orally
as suspension with gum acacia in NS, 1 hour before inject-
ing FCA on day 0 and then daily either for 4 days or for 28
days at doses based on our earlier studies where no observ-
able toxic eﬀects were seen [17, 20, 21], Group III: MeDL
(50mg/kg, MeDL 50); Group IV: MeDL (500mg/kg, MeDL
500); Group V: rofecoxib (20mg/kg, Rofe 20); Group VI: ro-
fecoxib (100mg/kg, Rofe 100); Group VII: phenylbutazone
(100mg/kg, PBZ).
2.4. Determinationoflevelsofoxidativestress
parametersandinﬂammatorymediators
The levels of biochemical markers of oxidative stress and
inﬂammatory mediators were determined at the site of in-
ﬂammation. Animals were sacriﬁced at the time of peak in-
ﬂammation (day 4) and the tissue of the arthritic joint was
removed and processed for the estimation of glutathione
(GSH, mg/g tissue) [22], catalase (U/mg protein) [23], su-
peroxide dismutase (SOD, U/mg protein) [24], glutathione
peroxidase (GPx, U/mg protein) [25], thiobarbituric acid-
reactive substances (TBARSs) as a measure of malondialde-
hyde (MDA, nmol/g tissue) [26], nitric oxide (NO, μM/mg
tissue)[27],prostaglandinE2 (PGE2,pg/mgtissue,R&DSys-
tems), tumor necrosis factor-α (TNF-α, pg/mg tissue, Dia-
cloneResearch),andmyeloperoxidase(MPO,OD/mgtissue)
[28] levels.
2.5. Estimationofprotein
The protein concentration of the samples was determined by
Bradford’s method [29].
2.6. Histologicalanalysis
Ratsweresacriﬁcedonday28,thelimbswereremovedabove
the stiﬂe joints, degloved and ﬁxed in 1% formaldehyde in
saline. They were decalciﬁed in EDTA, processed for paraﬃn
embedding, sectioned, and stained with hematoxylin-eosin
[30]. The sections were examined for arthritic changes in the
c o n t r o la sw e l la si nt h ed r u g - t r e a t e dr a t s .
2.7. Statisticalanalysis
The values are expressed as mean ± SEM of six observations
and ANOVA was used to compare the groups. The statistical
analysis was carried out by the version 10 of the SPSS pro-
gramandthevaluesofP<. 05wereconsideredasstatistically
signiﬁcant.
3. RESULTS
3.1. EffectofMeDLonjointinﬂammation
Injection of FCA into right ankle joint of rat produced an in-
crease in joint diameter that was maximum on day 4 (2.17 ±
0.13mm), and thereafter it gradually declined. Injection of
NS on the other hand produced a marginal increase in the
joint diameter on day 2 (0.04 ± 0.10mm) that returned to
normal within 4 days (Figure 1).
The inhibitory eﬀect of various drugs was evaluated on
the day of peak inﬂammation, that is, day 4. Oral admin-
istration of MeDL produced a dose-dependent decrease inV. L. Kumar and S. Roy 3
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Figure 1: Time course for increase in joint diameter in FCA-
induced monoarthritis in rats. Values are mean ± SEM.
joint inﬂammation and the increase in joint diameter was
1.59 ± 0.09mm and 1.20 ± 0.08mm in MeDL 50 and MeDL
500 groups against 2.17±0.13mm in FCA control (27% and
45% inhibition). COX-2 selective inhibitor, rofecoxib, was
more eﬀective in inhibiting joint inﬂammation as compared
to MeDL. The increase in joint diameter in Rofe 20 and Rofe
100 groups was 1.66 ± 0.08mm and 0.70 ± 0.33mm (24%
and68%inhibition).PBZ,anonselectiveCOXinhibitorpro-
duced 16% inhibition in joint inﬂammation with the in-
crease in joint diameter of 1.82 ±0.12mm (Table 1).
3.2. EffectofMeDLontissuelevelsof
inﬂammatorymediators
The inﬂammation induced by FCA was associated with an
increase in the levels of PGE2 and TNF-α. The tissue levels
of PGE2 and TNF-α were 7.35 ± 0.14 and 71.5 ± 5.00pg/mg
tissue in the FCA control as compared to 1.00 ± 0.01 and
2.50 ± 5.00pg/mg tissue in normal control rats, respectively.
Both MeDL and rofecoxib produced a signiﬁcant decrease in
the levels of PGE2 and TNF-α (P<. 005). The levels of PGE2
in MeDL 500 group were 0.6 ± 0.05, and in Rofe 100 group
were 1.00±0.23, and that of TNF-α in MeDL 500 group were
14.50±15.00,andinRofe100groupwere10.50±5.00pg/mg
tissue, respectively. PBZ on the other hand was not eﬀective
in reducing the tissue PGE2 levels and was only marginally
eﬀective in reducing the tissue TNF-α levels (Figure 2). FCA
injection produced a signiﬁcant increase in tissue MPO ac-
tivity from 0.06 ± 0.0 1O D / m gt i s s u ei nn o r m a lc o n t r o lr a t s
to 1.33±0.11OD/mgtissue.TreatmentwithMeDLandrofe-
coxib signiﬁcantly reduced the tissue MPO activity and their
eﬀect was comparable in this regard. The MPO levels were
0.14 ± 0.02 and 0.09 ± 0OD/mg tissue in MeDL 500 and
Rofe 100 group, respectively. PBZ on the other hand was
marginally eﬀective in decreasing the MPO levels as com-
pared to FCA control (1.00 ±0.03 versus 1.33 ±0.11OD/mg
tissue) (Figure 2). MeDL and rofecoxib were also equieﬀec-
tive in reducing the tissue NO levels in the arthritic rats
(2.0 ± 0.11 and 2.8 ± 0.10 against 5.9 ± 0.50μM/mg tissue
Table 1: Inhibition of joint inﬂammation by various drugs in FCA-
induced monoarthritis. Values given are mean ± SEM (n = 6).
Treatment
groups
Dose
(mg/kg)
Increase in joint
diameter (mm) Inhibition (%)
Normal control — — —
FCA control — 2.17 ±0.13 —
MeDL 50 1.59 ±0.09 27%
MeDL 500 1.20 ±0.08∗ 45%
Rofecoxib 20 1.66 ±0.08∗ 24%
Rofecoxib 100 0.70 ±0.33∗ 68%
Phenylbutazone 100 1.82 ±0.12 16%
∗P<. 05.
in FCA control). The eﬀect of PBZ in this regard was com-
parable to that of MeDL and rofecoxib (3.0 ± 0.04μM/mg
tissue) (Figure 2).
3.3. EffectofMeDLontissuelevelsofGSH,
catalase,SOD,GPx,andTBARS
Oxidative stress associated with FCA-induced monoarthri-
tis was evaluated by measuring the levels of GSH, catalase,
SOD, GPx, and TBARS in the inﬂamed joint tissue. FCA
injection into the ankle joint markedly decreased the tissue
GSH, catalase, SOD, and GPx levels from 18.20 ± 1.10mg/g
tissue, 28.60 ± 0.15U/mg protein, 277.70 ± 0.15U/mg pro-
tein, and 31.40±0.10U/mg protein in normal control rats to
4.80 ± 0.40mg/g tissue, 0.17 ± 0.02U/mg protein, 79.90 ±
0.10U/mg protein, and 5.97 ± 0.05U/mg protein, respec-
tively. Both MeDL and rofecoxib produced a dose-dependent
increase in the level of these oxidative stress parameters. On
the other hand, FCA produced a marked increase in the lev-
els of TBARS from 3.50 ± 0.50nmol/g tissue to 103.00 ±
3.00nmol/g tissue. Both MeDL and rofecoxib produced a
dose-dependent decrease in the levels of TBARS and the ef-
fect of these drugs was comparable. PBZ, on the other hand,
produced a marginal change in the levels of all the oxidative
stress parameters as compared to FCA control (Table 2).
3.4. EffectofMeDLonjointhistology
TheinﬂammationinducedbyFCAwasassociatedwithcellu-
lar inﬁltration, edema, granuloma formation, and bone de-
s t r u c t i o no nd a y2 8( Figure 3(b)).
Both MeDL 500 and Rofe 100 signiﬁcantly decreased the
arthritic changes as compared to FCA control, however, ro-
fecoxib was more eﬀective in this regard (Figures 3(c) and
3(d)).
4. DISCUSSION
The latex of Calotropis procera is well known for its anti-
inﬂammatory properties in various experimental models. It
has also been shown to aﬀord protection against functional
impairment produced by FCA in rat model of monoarthri-
tis. In the present study, we have evaluated the eﬀect of latex4 Mediators of Inﬂammation
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Figure 2: Eﬀe c to fd r u g so nt h et i s s u el e v e lo fP G E 2,T N F - α, MPO, and NO in FCA-induced monoarthritis in rats. Values are mean ± SEM.
∗P<0.05, ∗∗P<0.001.
of C. procera on the levels of inﬂammatory mediators, oxida-
tive stress parameters, and joint histology in FCA-induced
monoarthritis model and compared it with rofecoxib. Intra-
articular injection of FCA produced a peak inﬂammatory
response in the joint on day 4 that is associated with ﬂuid
exudation, neutrophil inﬁltration, and mast cell activation
[31, 32]. This was followed by a slow regression and the joint
swelling continued up to day 28 possibly due to oil-based ad-
juvant and the antigenicity of mycobacterium [33]. The in-
hibitory eﬀect of drugs was evaluated against FCA-induced
inﬂammation on day 4. MeDL produced a dose-dependent
inhibition in joint inﬂammation that could be attributed to
its ability to inhibit cellular inﬂux and vascular permeability
[17,20].Ithasearlierbeenshowntoinhibitinﬂammatoryre-
sponse induced by various mediators and inﬂammagens like
histamine,bradykinin, prostaglandins,carragenin,andcom-
pound 48/80 [17]. The role of various inﬂammatory media-
tors in adjuvant-induced arthritis has been well established
[34, 35]. In our study, rofecoxib, a selective COX-2 inhibitor,
was found to be more eﬀective than MeDL and phenylbuta-
zoneininhibitingtheFCA-inducedjointinﬂammationasre-
ported earlier by Kumar et al. [21] and Francischi et al. [36].
Rofecoxib acts by inhibiting COX-2 that plays an important
role in an inﬂammatory response. The greater eﬃcacy of ro-
fecoxib could be attributed to its better distribution at the
site of inﬂammation as suggested for other COX-2 inhibitors
[37]. Further, rofecoxib was also found to be more eﬀective
as compared to MeDL in inhibiting cell inﬂux and bone de-
struction as revealed by histological analysis. The inhibitory
eﬀect of MeDL and rofecoxib on cell inﬂux was further sub-
stantiatedbytheirabilitytodecreasetissueMPOactivitythat
has been used as an index of granulocyte inﬁltration. It is in-
teresting tonotethatPBZproducedonlyamarginaldecrease
intissueMPOactivity.TheinabilityofPBZtoinhibitcellular
inﬂux has also been reported by Meacock and Kitchen [38]
and Arya and Kumar [17].
The neutrophilic recruitment at the site of inﬂamma-
tion has been reported to involve TNF-α production thatV. L. Kumar and S. Roy 5
Table 2: Eﬀect of drugs on parameters of oxidative stress in FCA-induced monoarthritis. Values given are mean ± standard error of the
mean (n = 6).
Groups GSH Catalase SOD GPx TBARS
(mg/g tissue) (U/mg protein) (U/mg protein) (U/mg protein) (nmol/g tissue)
Normal control 18.20 ±1.10 28.60 ±0.15 277.70 ±0.15 31.40 ±0.10 3.50 ±0.50
FCA control 4.80 ±0.40 0.17 ±0.02 79.90 ±0.10 5.97 ±0.05 103.00 ±3.00
MeDL 50 7.30 ±0.40∗ 0.21 ±0.06 95.70 ±0.08 9.61 ±0.03∗ 77.50 ±6.50
MeDL 500 11.30 ±0.50∗∗ 20.10 ±0.01∗∗ 222.11 ±0.02∗∗ 29.52 ±0.11∗∗ 5.00 ±1.00∗∗
Rofecoxib 20 6.80 ±1.00 6.56 ±0.01∗ 137.16 ±0.03 6.55 ±0.08 64.00 ±7.00∗
Rofecoxib 100 14.30 ±0.90∗∗ 22.40 ±0.02∗∗ 236.62 ±0.10∗∗ 28.16 ±0.01∗∗ 5.50 ±0.50∗∗
PBZ 7.20 ±0.80∗ 4.16 ±0.06∗ 94.62 ±0.02 6.52 ±0.01 86.5 ±5.5
∗P<. 05.
∗∗P<. 001.
(a) (b)
(c) (d)
Figure 3: Eﬀect of drugs against FCA-induced arthritic changes as revealed by histological analysis: (a) normal control; (b) FCA control; (c)
MeDL 500mg/kg; (d) Rofe 100mg/kg.
inducesthesynthesisofLTB4,awell-knownchemoattractant
and prostaglandins that plays a key role in the pathogene-
sis of inﬂammatory diseases. Elevated levels of TNF-α and
prostaglandinshavebeenreportedinarthriticpatientsandin
experimentally induced arthritis [39, 40]. In our study, both
MeDLandrofecoxibproducedamarkedreductioninthetis-
sue levels of TNF-α and PGE2. However, PBZ was ineﬀective
in reducing the levels of PGE2 though it produced a signiﬁ-
cant decrease in tissue TNF-α levels. A marked reduction in
the levels of PGE2 brought about by MeDL was comparable
to that of rofecoxib and suggests that like rofecoxib, MeDL
might be inhibiting COX-2. Earlier, the MeDL was shown to
inhibit inﬂammation induced by PGE2 [17].
The role of NO has been well established in an inﬂam-
matory response. As the inﬂammatory response progresses,
large quantities of NO are generated through the induction
of iNOS (inducible nitric oxide synthase) that reacts with
superoxide anion to form peroxynitrate, a potent oxidizing
molecule capable of eliciting lipid peroxidation. Lipid per-
oxidation is the oxidative deterioration of polyunsaturated
lipids to form radical intermediates that bring about cellular
damage. MDA, a major end product of this reaction, is an in-
dex of lipid peroxidation and has been estimated as TBARS
[41]. In our study, both MeDL and rofecoxib brought down
the tissue levels of NO and TBARS. Besides, the inﬁltrating
cells also generate reactive oxygen species and free radicals
that bring about destruction of the inﬂamed joint. As a re-
sult, the scavenging enzyme SOD that leads to the formation
of hydrogen peroxide is utilized and its activity is reduced in
arthritic rats. The hydrogen peroxide thus generated is de-6 Mediators of Inﬂammation
composed by catalase and glutathione peroxidase. Excessive
productionoflipidhydroperoxidemayalsocontributetode-
creased activity of GPx in arthritic condition [42]. Beside
enzymatic antioxidants, the level of glutathione, a nonenzy-
matic reducingagentthattrapsfreeradicals andpreventsox-
idative stress, is also decreased in arthritis [43]. Both MeDL
and rofecoxib maintained the oxidative homeostasis, and the
levels of GSH and activities of catalase, SOD, and GPx were
comparable to the control animals. The antioxidant proper-
ties of rofecoxib and latex of C. procera have also been re-
ported earlier [44, 45].
Thus, present study shows that the latex of C. procera
markedly reduces cellinﬂux, releaseof mediators, and oxida-
tive stress associated with arthritic condition, and therefore
has the potential to be used as an antiarthritic agent.
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